Feldan Therapeutics is a biotechnology company developing therapeutic indications based on the use of an innovative technology developed internally, the Feldan Shuttle. This technology is a peptide-based delivery system that can bring proteins, antisense oligonucleotides, peptides and small molecules in cells, organs, and tissues. It can be used either by local administration or systemic administration. Currently, Feldan’s focus is to develop a topical drug for Gorlin Syndrome, and the company’s objective is to reach first-in-human Phase I/II clinical trial in mid-2021. The development of other programs centered on skin diseases is ongoing, as well as the development of an undisclosed systemic program.